Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy
about
Current status and perspectives of immune-based therapies for hepatocellular carcinomaAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesImmunotherapeutic approaches for hepatocellular carcinomaInhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Cellular immunity augmentation in mainstream oncologic therapyCancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine.Cervical cancer systemic inflammation score: a novel predictor of prognosisSunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitmentTherapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Targeting tumour microenvironment by tyrosine kinase inhibitor.Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
P2860
Q26772326-331DCC06-28E3-4012-84D3-4A9D4EFAD49EQ26774312-DFA27F78-CAF6-4D05-A8AB-F0DFA6AF3A9AQ33779723-76012666-BA39-43D0-BD97-B6B172117AE6Q36286833-E6756B00-ACAB-479B-88A4-849EF6DF39E1Q36831553-98B1051A-F840-4DD9-BAFD-EFFB6E265AE1Q38557424-99B2DCCF-C657-4723-B898-77497E1B01E2Q38600417-CF895945-A35E-4105-9BB6-A72C9836C116Q38803271-1A784604-4531-425A-A2C4-F063B9C0F4AFQ38829551-2986FCF7-62E0-4D95-B9AA-FEABE23A23CBQ39991182-6D2D59FB-D14E-42E7-BF2B-3FD7C56F7F67Q41269256-08558E42-3F8D-4D84-8128-1AF48DAB9FA9Q47134647-B3321780-6735-4561-BA5F-20E85BB06EEBQ47440377-B484C291-8089-430F-9B87-486ADFF293CEQ47861428-EBBBC1B0-776C-4D2A-BC47-825663D0EE75Q49315568-E61EF26A-5E6A-4BF8-9243-8311D9B71234Q49887906-98049E1D-2223-43C5-99A9-825A7D1FA304Q50544084-0B973085-313A-4078-9F36-0E53D6AA3BA5Q54981236-B72C2626-1896-4AA7-86C2-9245477FD12D
P2860
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@ast
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@en
type
label
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@ast
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@en
prefLabel
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@ast
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@en
P2093
P2860
P356
P1476
Immune consequences of tyrosin ...... gize with cancer immunotherapy
@en
P2093
Anna R Kwilas
James W Hodge
Kwong Y Tsang
Renee N Donahue
P2860
P356
10.14800/CCM.677
P577
2015-01-01T00:00:00Z